CA2847604A1 - Removal of contaminating viruses from aav preparations - Google Patents

Removal of contaminating viruses from aav preparations Download PDF

Info

Publication number
CA2847604A1
CA2847604A1 CA2847604A CA2847604A CA2847604A1 CA 2847604 A1 CA2847604 A1 CA 2847604A1 CA 2847604 A CA2847604 A CA 2847604A CA 2847604 A CA2847604 A CA 2847604A CA 2847604 A1 CA2847604 A1 CA 2847604A1
Authority
CA
Canada
Prior art keywords
filter
virus
sample
virions
baculovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2847604A
Other languages
English (en)
French (fr)
Inventor
Wilhelmus Theodorus Johannes Maria Christiaan Hermens
James Patrick Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uniqure IP BV
Original Assignee
Uniqure IP BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47832422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2847604(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Uniqure IP BV filed Critical Uniqure IP BV
Publication of CA2847604A1 publication Critical patent/CA2847604A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06—Organic material
    • B01D71/08—Polysaccharides
    • B01D71/10—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2623—Ion-Exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2649—Filtration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2847604A 2011-09-08 2012-09-07 Removal of contaminating viruses from aav preparations Abandoned CA2847604A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161532176P 2011-09-08 2011-09-08
EP11180594.1 2011-09-08
EP11180594 2011-09-08
US61/532,176 2011-09-08
PCT/NL2012/050619 WO2013036118A1 (en) 2011-09-08 2012-09-07 Removal of contaminating viruses from aav preparations

Publications (1)

Publication Number Publication Date
CA2847604A1 true CA2847604A1 (en) 2013-03-14

Family

ID=47832422

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2847604A Abandoned CA2847604A1 (en) 2011-09-08 2012-09-07 Removal of contaminating viruses from aav preparations

Country Status (19)

Country Link
US (3) US9840694B2 (https=)
EP (3) EP3425044A1 (https=)
JP (2) JP6198278B2 (https=)
KR (1) KR101961347B1 (https=)
CN (2) CN107502597A (https=)
AU (1) AU2012304993B2 (https=)
BR (1) BR112014005255A2 (https=)
CA (1) CA2847604A1 (https=)
DK (1) DK2744895T3 (https=)
EA (1) EA027511B1 (https=)
ES (1) ES2558168T3 (https=)
HU (1) HUE026579T2 (https=)
IL (1) IL231398A (https=)
MX (1) MX349601B (https=)
PL (1) PL2744895T3 (https=)
PT (1) PT2744895E (https=)
SI (1) SI2744895T1 (https=)
WO (1) WO2013036118A1 (https=)
ZA (1) ZA201401714B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2744895E (pt) * 2011-09-08 2016-02-08 Uniqure Ip Bv Remoção de vírus contaminantes de preparações de aav
CN120174012A (zh) 2013-10-24 2025-06-20 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
FI3224376T4 (fi) * 2014-11-28 2023-08-31 Dna-epäpuhtaudet koostumuksessa, joka käsittää parvovirusvirionin
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
AU2015370903B2 (en) 2014-12-24 2021-06-17 Uniqure Ip B.V. RNAi induced huntingtin gene suppression
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
US20200263199A1 (en) 2017-09-29 2020-08-20 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
SG11202006056RA (en) 2018-01-17 2020-07-29 Meiragtx Uk Ii Ltd A modified raav capsid protein for gene therapy
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
EP3850098A1 (en) 2018-09-12 2021-07-21 uniQure IP B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
JP2022514112A (ja) * 2018-10-15 2022-02-09 リジェネクスバイオ インコーポレイテッド 複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法
WO2020104480A1 (en) 2018-11-19 2020-05-28 Uniqure Biopharma B.V. Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
CA3119721A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. A companion diagnostic to monitor the effects of gene therapy
WO2020104469A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. Method and means to deliver mirna to target cells
WO2020104295A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3
JP2022522995A (ja) * 2019-01-18 2022-04-21 ボイジャー セラピューティクス インコーポレイテッド Ａａｖ粒子を生成するための方法及びシステム
US11718834B2 (en) 2019-02-15 2023-08-08 Sangamo Therapeutics, Inc. Compositions and methods for producing recombinant AAV
WO2020219897A1 (en) * 2019-04-24 2020-10-29 Biogen Ma Inc. Methods for production of recombinant adeno-associated viruses
PL3999119T3 (pl) 2019-07-15 2025-02-10 Meiragtx Uk Ii Limited Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów
WO2021053018A1 (en) 2019-09-16 2021-03-25 Uniqure Ip B.V. Targeting misspliced transcripts in genetic disorders
IL293397A (en) 2019-12-04 2022-07-01 Sangamo Therapeutics Inc New preparations and methods for the production of recombinant aav
JP7737374B2 (ja) * 2019-12-12 2025-09-10 イー・エム・デイー・ミリポア・コーポレイシヨン 透析濾過緩衝液を用いて増強したウイルス濾過
WO2021154923A2 (en) * 2020-01-29 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
JP7390466B2 (ja) * 2020-02-28 2023-12-01 旭化成メディカル株式会社 ウイルスクリアランス性能の評価方法
CA3174872A1 (en) 2020-04-07 2021-10-14 Sander Jan Hendrik Van Deventer Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof
CN115427561B (zh) 2021-03-09 2024-06-04 辉大(上海)生物科技有限公司 工程化CRISPR/Cas13系统及其用途
US20240157306A1 (en) * 2021-03-30 2024-05-16 3M Innovative Properties Company Hollow-fiber membrane and method making thereof
CN117120152A (zh) * 2021-03-30 2023-11-24 3M创新有限公司 包含聚砜和聚噁唑啉的中空纤维膜及其制造方法
WO2022214635A1 (en) 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
CA3219847A1 (en) 2021-06-02 2022-12-08 Sander Jan Hendrik Van Deventer Adeno-associated virus vectors modified to bind high-density lipoprotein
EP4359525A1 (en) 2021-06-21 2024-05-01 uniQure biopharma B.V. Gene constructs for silencing alpha-synuclein and uses thereof
CN117836010A (zh) 2021-06-21 2024-04-05 优尼科生物制药有限公司 改进的裂解程序
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
EP4508213A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Nucleic acid regulation of apoe
EP4508215A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Novel systems for nucleic acid regulation
WO2023198663A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of snca
WO2023198702A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of c9orf72
US20240209324A1 (en) * 2022-12-22 2024-06-27 Cytiva Us Llc Virus separation
EP4698555A1 (en) 2023-04-18 2026-02-25 uniQure biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
WO2024218204A1 (en) 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Gene delivery vehicles comprising rna and antibodies
AU2024313758A1 (en) 2023-06-23 2026-01-08 Uniqure Biopharma B.V. Novel fragile x constructs
AU2024337260A1 (en) 2023-09-04 2026-03-12 Uniqure Biopharma B.V. Novel neurotropic recombinant adeno-associated virus particles
AU2024357870A1 (en) 2023-10-11 2026-04-23 Uniqure Biopharma B.V. Further novel systems for nucleic acid regulation
AU2024360616A1 (en) 2023-10-11 2026-04-23 Uniqure Biopharma B.V. Novel nucleic acid regulation of huntingtin gene
WO2025078602A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Nucleic acid regulation of msh3 in repeat expansion disorders
WO2025114524A1 (en) 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations for viral drug products
WO2025219443A1 (en) 2024-04-19 2025-10-23 Uniqure Biopharma B.V. Nucleic acid for a1at regulation
WO2026041788A1 (en) 2024-08-22 2026-02-26 Uniqure Biopharma B.V Novel bbb interacting capsids
WO2026041782A1 (en) 2024-08-22 2026-02-26 Uniqure Biopharma B.V. Novel raav capsids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
WO1996011272A2 (de) 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
DE19709186C2 (de) 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
ES2340230T3 (es) 1998-11-10 2010-05-31 University Of North Carolina At Chapel Hill Vectores viricos y sus procedimientos de preparacion y administracion.
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
US20050009168A1 (en) * 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
KR101589259B1 (ko) * 2006-06-21 2016-02-01 유니큐어 아이피 비.브이. 곤충세포 내 ａａｖ의 생산에 유용한 ａａｖ-ｒｅｐ78의 번역을 위한 변형된 개시 코돈을 갖는 벡터
WO2008109721A1 (en) * 2007-03-06 2008-09-12 Introgen Therapeutics, Inc. Chromatographic methods for assessing adenovirus purity
US20100323429A1 (en) * 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
HUE028341T2 (en) 2009-06-16 2016-12-28 Genzyme Corp Improved methods for purification of recombinant aav vectors
DK2529020T3 (en) * 2010-01-28 2018-08-06 Childrens Hospital Philadelphia SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
PT2744895E (pt) 2011-09-08 2016-02-08 Uniqure Ip Bv Remoção de vírus contaminantes de preparações de aav

Also Published As

Publication number Publication date
US9840694B2 (en) 2017-12-12
SI2744895T1 (sl) 2016-03-31
EA027511B1 (ru) 2017-08-31
IL231398A0 (en) 2014-04-30
JP6198278B2 (ja) 2017-09-20
JP2014526246A (ja) 2014-10-06
EP3425044A1 (en) 2019-01-09
HUE026579T2 (en) 2016-06-28
ES2558168T3 (es) 2016-02-02
PT2744895E (pt) 2016-02-08
EA201490583A1 (ru) 2014-07-30
DK2744895T3 (en) 2016-01-04
US10253301B2 (en) 2019-04-09
EP2990477A1 (en) 2016-03-02
EP2744895B1 (en) 2015-10-14
KR101961347B1 (ko) 2019-03-25
CN103857790B (zh) 2017-09-08
PL2744895T3 (pl) 2016-04-29
KR20140074333A (ko) 2014-06-17
BR112014005255A2 (pt) 2017-04-04
US20190218523A1 (en) 2019-07-18
ZA201401714B (en) 2015-12-23
AU2012304993A1 (en) 2014-03-20
MX2014002733A (es) 2014-07-14
WO2013036118A1 (en) 2013-03-14
AU2012304993B2 (en) 2017-09-14
EP2744895A1 (en) 2014-06-25
CN107502597A (zh) 2017-12-22
US20140342434A1 (en) 2014-11-20
EP2990477B1 (en) 2018-08-29
IL231398A (en) 2017-06-29
CN103857790A (zh) 2014-06-11
US20180100143A1 (en) 2018-04-12
HK1220229A1 (en) 2017-04-28
MX349601B (es) 2017-08-04
JP6624690B2 (ja) 2019-12-25
EP2990477B8 (en) 2018-10-31
JP2018023365A (ja) 2018-02-15

Similar Documents

Publication Publication Date Title
US10253301B2 (en) Removal of contaminating viruses from AAV preparations
KR102930150B1 (ko) 재조합 aav 생성을 위한 음이온 교환 크로마토그래피
JP6735672B2 (ja) アデノ随伴ウイルス第ｖｉｉｉ因子ベクター
ES2472429T3 (es) Método para la purificación de partículas de adenovirus a partir de cultivos de alta densidad celular
JP2023098990A (ja) トリコプルシア・ニの蛹における組み換えタンパク質の発現
US20030036088A1 (en) Filtration process for separating viruses
US20240287545A1 (en) Improved lysis procedures
Tijssen et al. Parvoviridae. Structure and reproduction of densonucleosis viruses
HK1220229B (en) Removal of contaminating viruses from aav preparations
HK1262994A1 (en) Removal of contaminating viruses from aav preparations
Michalsky et al. Concentration of the baculovirus Autographa californica M nucleopolyhedrovirus (AcMNPV) by ultrafiltration
US20050009168A1 (en) Methods and apparatus for Adeno associated virus purification
Michalsky et al. Purification of the baculovirus Autographa californica M nucleopolyhedrovirus by tangential flow ultrafiltration
Zhou et al. Characterization of two density populations of feline calicivirus particles
JP7588466B2 (ja) パルボウイルスの生産方法
WO2024054983A1 (en) Controlled expression of viral proteins

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170828

FZDE Discontinued

Effective date: 20230307